TABLE OF CONTENTS. 4. Formulation Opportunities Oral Reformulation Taste Masking MCD GROUP, LLC October

Size: px
Start display at page:

Download "TABLE OF CONTENTS. 4. Formulation Opportunities Oral Reformulation Taste Masking MCD GROUP, LLC October"

Transcription

1 TABLE OF CONTENTS 1. Executive Summary... 9 Market Overview... 9 Drug Delivery Systems for Pediatrics Formulation Opportunities Specialty Pediatric Companies Product Licensing Opportunities Pediatric Market Overview Market Needs Therapeutic Needs Hypertension Hypercholesterolemia Diabetes Pain Management Anti-Infectives Respiratory / Allergy Attention Deficit Hyperactivity Disorder Epilepsy Market Size Key Therapeutic Areas CNS Allergies Asthma Infections Drug Delivery Systems for Pediatrics Marketed Products Dosage Forms Taste Masking Orally Disintegrating Dosage Forms Soft Chewable Delivery Systems Oral Liquid Delivery Systems Oral Mucosal Delivery Systems Transdermal Delivery Systems Topical Delivery Systems Nasal Drug Delivery Pulmonary Delivery Systems Parenteral and Device Technologies Formulation Opportunities Oral Reformulation Taste Masking

2 Non-invasive Formulations Companies with Pediatric Focus Adamis Pharmaceuticals Corporation Aires Pharmaceuticals, Inc Arbor Pharmaceuticals, Inc Asklepion Pharmaceuticals, Inc Centrix Pharmaceutical, Inc Cornerstone Therapeutics, Inc Curemark, LLC FSC Pediatrics, Inc InfaCare Pharmaceutical Corporation Lupin Pharmaceuticals, Inc Madeira Therapeutics McNeil Pediatrics Meritage Pharma, Inc Next Wave Pharmaceuticals, Inc ParaPRO, LLC Pediapharm, Inc Pernix Therapeutics Holdings, Inc Reckitt Benckiser Pharmaceutical, Inc Seaside Therapeutics, Inc Shionogi Pharma, Inc TaroPharma Teva Respiratory, LLC Tiber Laboratories, LLC Topaz Pharmaceuticals, Inc TRx Pharma Drug Delivery Technologies for Pediatric Drugs Buccal Delivery Systems APTYS Pharmaceuticals Biodel, Inc BioDelivery Sciences International Corium International, Inc Fertin Pharma NovaDel Pharma Orexo AB ULURU, Inc Watson, Inc Oral Delivery Systems Acino Holding, Ltd Akina, Inc Alpex Pharma Alte Biosciences, Inc

3 Aprecia Pharmaceuticals Company Arx, LLC Banner Pharmacaps Capricorn Pharma, Inc Catalent Pharma Solutions CIMA Labs, Inc Collegium Pharmaceutical, Inc Dow Wolff Cellulosics Egalet A/S Ethypharm Eurand, Inc Eurand, Inc ForTe BV Grunenthal GmbH HealthSport, Inc IntelGenx Corporation KV Pharmaceutical Company Labtec Pharma Lavipharm Losan Pharma GmbH LTS Lohmann Meldex International, PLC MonosolRx NAL Pharmaceuticals, Ltd Pharmafilm S.r.l Physica Pharma SPI Pharma Inc Tris Pharma Xel Pharmaceuticals, Inc Taste Masking Technologies Balchem Corporation Cambrex Corporation Ethypharm Eurand, Inc ForTe BV Oralance Pharma Nasal Technologies Ikano Therapeutics, Inc OptiNose Dermal Delivery Technologies Altea Therapeutics Foamix, Ltd ForTe BV Intercell

4 nanobiosciences, LLC Pantec Biosolutions Quinnova Pharmaceuticals, Inc TransPharma Medical Zosano Pharma Product Licensing Opportunities Albuterol Dry Powder Inhaler Allergy Chewing Gum Atopic Dermatitis Treatment Atopiclair TM Cream CRO-PED for Pediatric Diarrhea Children s Dietary Supplement Ciprofloxacin Otic Solution Cough/Cold Pediatric Formulations Decongestant Cream Stick Decongestant Patch Fever Cooling Patch Foam-Based Dermatology Products Foam-Based Products for Infants GastroGard-R for Rotavirus Hedrin TM for the Treatment of Head Lice Human Growth Hormone Nasal Spray Insect Repellent Patch Insecticide-Free Head Lice Treatment Liposomal Amikacin Formulation Long-acting Somatropin Injection Moisturizing Cream for Dermatitis Nasal Somatropin Formulation NeoCeram TM Skin Barrier Emulsion Novel Head Lice Formulation Once-weekly Injectable Somatropin Oral Film Formulation of Prednisolone Oral Rotavirus Thin Film Product Orally Disintegrating Acetaminophen Formulations Orally Disintegrating Allergy Products Pediatric Pain Formulations Peptide for Chronic Middle Ear Infections Sinlice, Pediculicide Treatment Site-Specific Otitis Media Treatment Sustained Release Somatropin Injection Teething Gel for Babies Zinc Oxide Spray

5 INDEX OF TABLES Table 1: Pediatric Age Related Subgroups Table 2: Antihypertensives Granted Pediatric Exclusivity Table 3: Cholesterol Drugs Granted Pediatric Exclusivity Table 4: Diabetes Products Used in Pediatrics Table 5: Pain Medications Granted Pediatric Exclusivity Table 6: Emerging Technologies for Antibiotics Table 7: Leading Respiratory/Allergy Products for Pediatrics Table 8: ADHD Medications for Pediatrics Table 9: Drugs Approved for Epilepsy Figure 1: US Prescription Pediatric Market, Table 10: Sales of 25 Drugs Commonly Prescribed to Pediatrics Table 11: Sales of Leading Pediatric-Focused Products, Table 12: Sales of Leading ADHD Drugs, Table 13: Sales of Leading Prescription Allergy Drugs, Table 14: Sales of Leading Asthma Drugs, Table 15: Pediatric Oral Antibiotic Market Table 16: DDS Products Approved for Pediatric Use Table 17: OTC DDS Products for Pediatrics Table 18: Key Players in Taste Masking Table 19: ODT Technology Summary Table 20: Key Players in ODT Market Table 21: Oral Film Technology Summary Table 22: Key Players in Oral Film Market Table 23: ODD Pipeline Products for Pediatrics Table 24: Advantages of Chewable Dosage Forms Table 25: Soft Chewable Delivery Systems Table 26: Liquid Drug Delivery Technologies Table 27: Liquid Pediatric Products in Development Table 28: Key Players in Buccal Delivery Table 29: Transdermal Pediatric Products Table 30: Transdermal Pipeline for Pediatrics Table 31: Topical Pediatric Pipeline Table 32: Nasal Pipeline Products Applicable to Pediatrics Table 33: Pulmonary Pipeline for Pediatrics Table 34: Parenteral DDS Pediatric Pipeline Table 35: Pediatric Drug Candidates for Oral Reformulation Table 36: Taste Masking Development Opportunities Table 37: Non-invasive Reformulation Opportunities Table 38: Arbor Product Pipeline Table 39: Asklepion Pipeline Table 40: Pediatric Products of Centrix Table 41: Therapeutic Targets of Centrix

6 Table 42: Cornerstone Products Prescribed to Pediatrics Table 43: Madeira Product Pipeline Table 44: McNeil s Pediatric Product Developments Table 45: NextWave Pipeline Products Table 46: Pediapharm Pipeline Table 47: Marketed Products by Reckitt Benckiser Table 48: Pediatric Products Marketed by Shionogi Table 49: Shionogi Pediatric Pipeline Table 50: NonSpil OTC Products Table 51: Rx Products Marketed by Taro Table 52: Teva s Key Products for Pediatrics Table 53: Tiber Laboratories Product Portfolio Table 54: VIAdel Pipeline Table 55: NovaDel Pipeline Table 56: Orexo s Sublingual Pipeline Table 57: Alpex Pipeline Table 58: Marketed Zydis Products Table 59: Catalent Product Pipeline Table 60: Products Developed by CIMA Table 61: Ethypharm s ODT Products Table 62: Eurand s ODT Products Table 63: HealthSport Products Table 64: Labtec Products Table 65: LTS Wafer Systems Table 66: Meldex DDS Pipeline Table 67: MonosolRx Pipeline Table 68: Malt-o-Fast Comparative Data Table 69: Tris Product Pipeline Table 70: Products Containing Microcaps Technology Table 71: NODS Pipeline Table 72: OptiNose Pipeline Table 73: PassPort TM Product Pipeline Table 74: ViaDerm Pipeline Table 75: Foamix Pipeline Products

Assessment of Human Pharmaceutical Products Registered in Kenya by Route of Administration and Type of Dosage Form

Assessment of Human Pharmaceutical Products Registered in Kenya by Route of Administration and Type of Dosage Form 38 East and Central African Journal of Pharmaceutical Sciences Vol. 15 (2012) 38-46 Assessment of Human Pharmaceutical Products Registered in Kenya by Route of Administration and Type of Dosage Form N.N.

More information

2/7/13. Andrea Rhodes, PharmD Undergraduate: Kansas State University and Wichita State University for prepharmacy

2/7/13. Andrea Rhodes, PharmD Undergraduate: Kansas State University and Wichita State University for prepharmacy Andrea Rhodes, PharmD Undergraduate: Kansas State University and Wichita State University for prepharmacy Graduated from University of Kansas School of Pharmacy in 2005 with Doctorate of Pharmacy Work

More information

Aradigm Corporation. A respiratory specialty pharmaceutical company fulfilling unmet needs in pulmonary medicine (ARDM) February 2008

Aradigm Corporation. A respiratory specialty pharmaceutical company fulfilling unmet needs in pulmonary medicine (ARDM) February 2008 Aradigm Corporation A respiratory specialty pharmaceutical company fulfilling unmet needs in pulmonary medicine (ARDM) February 2008 Safe Harbor Statement This presentation contains forward-looking statements

More information

ADDITIONAL DRUG LISTING FOR MEDICARE & MEDI-CAL MEMBERS

ADDITIONAL DRUG LISTING FOR MEDICARE & MEDI-CAL MEMBERS MEDICARE & MEDICAL MEMBERS! Please read carefully! The following pages include additional drugs which may be covered for you with your doctor s prescription by MediCal (Medicaid). These drugs CANNOT be

More information

For External Use Only. Should neither be swallowed. Nor injected

For External Use Only. Should neither be swallowed. Nor injected For External Use Only Should neither be swallowed Nor injected Preparations which are applied to the skin. (Topical preparations) Preparations which are applied to the mucus membranes. Local effect Systemic

More information

innovative products. faster to market. reliably supplied.

innovative products. faster to market. reliably supplied. innovative products. faster to market. reliably supplied. consumer health E DEVELOPMENT DELIVERY SUPPLY We create unique, tailored consumer health solutions to help your brand grow. With more differentiated

More information

Suboxone, Zubsolv, Bunavail (buprenorphine with naloxone sublingual tablets and film), Buprenorphine sublingual tablets

Suboxone, Zubsolv, Bunavail (buprenorphine with naloxone sublingual tablets and film), Buprenorphine sublingual tablets Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.32 Subject: Suboxone Drug Class Page: 1 of 7 Last Review Date: June 24, 2016 Suboxone Drug Class Description

More information

PHAR 7632 Chapter 7. Table Market and Share of Pharmaceuticals by ROA Data from Viswanathan, 2004

PHAR 7632 Chapter 7. Table Market and Share of Pharmaceuticals by ROA Data from Viswanathan, 2004 Student Objectives for this Chapter After completing the material in this chapter each student should:- be able to describe various routes of drug administration including the concentration versus time

More information

Medication Administration Curriculum INSTRUCTOR S MANUAL. Name State Date

Medication Administration Curriculum INSTRUCTOR S MANUAL. Name State Date Instructions: Circle the letter of the choice that best completes the statement or answers the question. If select modules were presented, only fill out the questions related to those modules. MODULE 1

More information

FDB FOOD AND DRUGS BOARD G H A N A GUIDELINES FOR CONDUCTING BIOEQUIVALENCE STUDIES

FDB FOOD AND DRUGS BOARD G H A N A GUIDELINES FOR CONDUCTING BIOEQUIVALENCE STUDIES FDB FOOD AND DRUGS BOARD G H A N A GUIDELINES FOR CONDUCTING BIOEQUIVALENCE STUDIES 1 SCOPE In pursuance of section 47 of the Food and Drugs Law 1992, P.N.D.C.L 305B, as amended by Act 523, 1996, these

More information

Dry Eye Syndrome - Current and Future Players. GDHC1016FPR / Published May 2013

Dry Eye Syndrome - Current and Future Players. GDHC1016FPR / Published May 2013 Dry Eye Syndrome - Current and Future Players GDHC1016FPR / Published May 2013 Executive Summary Significant growth is expected in the DES market from 2012-2022. GlobalData estimates 2012 DES therapeutic

More information

Lauren Silvernail, CFO & VP Corporate Development to present at 2005 Thomas Weisel Partners Healthcare Conference on September 7, 2005 at 3:50 pm EST

Lauren Silvernail, CFO & VP Corporate Development to present at 2005 Thomas Weisel Partners Healthcare Conference on September 7, 2005 at 3:50 pm EST Lauren Silvernail, CFO & VP Corporate Development to present at 2005 Thomas Weisel Partners Healthcare Conference on September 7, 2005 at 3:50 pm EST Forward Looking Statements Certain statements contained

More information

PHARMACEUTICS I صيدالنيات 1 UNIT 1 INTRODUCTION

PHARMACEUTICS I صيدالنيات 1 UNIT 1 INTRODUCTION PHARMACEUTICS I صيدالنيات 1 UNIT 1 INTRODUCTION 1 PHARMACEUTICS Pharmaceutics is the science of dosage form design. The general area of study concerned with the formulation, manufacture, stability, and

More information

Chapter 7. Principles of Pharmacology

Chapter 7. Principles of Pharmacology Chapter 7 Principles of Pharmacology Introduction Administering medications is a serious business. Medications may alleviate pain and improve patient s well-being. Used inappropriately, may cause harm

More information

MEDICINES FOR SMOKING CESSATION: GLOBAL MARKETS. PHM154A September Anand Gijare Project Analyst ISBN:

MEDICINES FOR SMOKING CESSATION: GLOBAL MARKETS. PHM154A September Anand Gijare Project Analyst ISBN: MEDICINES FOR SMOKING CESSATION: GLOBAL MARKETS PHM154A September 2013 Anand Gijare Project Analyst ISBN: 1-56965-544-8 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 866-285-7215, 781-489-7301

More information

MEDICATION OR OTHER SUBSTANCE

MEDICATION OR OTHER SUBSTANCE Patient Safety Event Report Hospital MEDICATION OR OTHER SUBSTANCE Use this form to report any patient safety event or unsafe condition involving a substance such as a medications, biological products,

More information

OVER-THE-COUNTER (OTC) DRUGS AND DIETARY SUPPLEMENTS: GLOBAL MARKETS

OVER-THE-COUNTER (OTC) DRUGS AND DIETARY SUPPLEMENTS: GLOBAL MARKETS OVER-THE-COUNTER (OTC) DRUGS AND DIETARY SUPPLEMENTS: GLOBAL MARKETS PHM050B February 2014 Anand Gijare Project Analyst ISBN: 1-56965-690-8 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA

More information

N a s d a q : I N S Y

N a s d a q : I N S Y N a s d a q : I N S Y 0 Safe Harbor Statement This presentation contains both historical information and forward-looking statements. Forward-looking statements are based on management's current expectations

More information

Smoking and Nicotine Replacement Therapy (NRT) Lec:5

Smoking and Nicotine Replacement Therapy (NRT) Lec:5 Smoking and Nicotine Replacement Therapy (NRT) Lec:5 Tobacco use remains the single largest preventable cause of mortality. Cigarette smoke is a complex mixture of an estimated 4800 compounds. Approximately

More information

MODULE 3 How to Administer Medication

MODULE 3 How to Administer Medication MODULE 3 How to Administer Medication Introduction: top common errors 5 Rights Identifying as needed conditions Universal/standard precautions Preparing to administer medication Medication administration

More information

MEDICATION OR OTHER SUBSTANCE

MEDICATION OR OTHER SUBSTANCE Patient Safety Event Report Hospital MEDICATION OR OTHER SUBSTANCE Use this form to report any patient safety event or unsafe condition involving a substance such as a medications, biological products,

More information

Medimetriks Highlights

Medimetriks Highlights Medimetriks Highlights Specialty pharma company targeting medical Dermatology Established commercial operations with a Sales Force approaching 40 strong in key US markets Marketed brands for treatment

More information

INFORMATION TOPIC: II-5 OR DEMONSTRATION: II-5. DOSAGE, MEASUREMENTS, AND DRUG FORMS (Lesson Title) OBJECTIVES THE STUDENT WILL BE ABLE TO:

INFORMATION TOPIC: II-5 OR DEMONSTRATION: II-5. DOSAGE, MEASUREMENTS, AND DRUG FORMS (Lesson Title) OBJECTIVES THE STUDENT WILL BE ABLE TO: LESSON PLAN: 5 COURSE TITLE: UNIT: II MEDICATION TECHNICIAN GENERAL PRINCIPLES SCOPE OF UNIT: This unit includes medication terminology, dosage, measurements, drug forms, transcribing physician s orders,

More information

Clinical Policy: CNS Stimulants Reference Number: CP.PMN.92 Effective Date: Last Review Date: Line of Business: Commercial, Medicaid

Clinical Policy: CNS Stimulants Reference Number: CP.PMN.92 Effective Date: Last Review Date: Line of Business: Commercial, Medicaid Clinical Policy: Reference Number: CP.PMN.92 Effective Date: 03.01.18 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Dow Wolff Cellulosics. Using ingenuity and savvy. TM Trademark of The Dow Chemical Company ( Dow ) or an affiliated company of Dow

Dow Wolff Cellulosics. Using ingenuity and savvy. TM Trademark of The Dow Chemical Company ( Dow ) or an affiliated company of Dow Dow Wolff Cellulosics Pharmaceutical Excipients Using ingenuity and savvy to help design healthcare solutions TM Trademark of The Dow Chemical Company ( Dow ) or an affiliated company of Dow Enhancing

More information

Pharmacy Program Updates: Quarterly Pharmacy Changes Effective July 1, 2017

Pharmacy Program Updates: Quarterly Pharmacy Changes Effective July 1, 2017 Pharmacy Program Updates: Quarterly Pharmacy Changes Effective July 1, 2017 DRUG LIST CHANGES Based on the availability of new prescription medications and Prime s National Pharmacy and Therapeutics Committee

More information

Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004

Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004 Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004 Disclaimer 2 This presentation contains forward-looking statements, i.e., current estimates or expectations

More information

ADVANCIA : A TRUE PLATFORM & INNOVATIVE SYSTEM OFFERING EFFICIENT NASAL DOSE DELIVERY

ADVANCIA : A TRUE PLATFORM & INNOVATIVE SYSTEM OFFERING EFFICIENT NASAL DOSE DELIVERY ADVANCIA : A TRUE PLATFORM & INNOVATIVE SYSTEM OFFERING EFFICIENT NASAL DOSE DELIVERY Millions of people suffering from allergic rhinitis use nasal sprays manufactured by Nemera every day. In this article,

More information

Pharmacy Prep. Qualifying Pharmacy Review

Pharmacy Prep. Qualifying Pharmacy Review Pharmacy Prep 2014 Misbah Biabani, Ph.D Director, Tips Review Centres 5460 Yonge St. Suites 209 & 210 Toronto ON M2N 6K7, Canada Luay Petros, R.Ph Pharmacy Manager, Wal-Mart, Canada 1 Disclaimer Your use

More information

11:00-11:50 AM 8:00-8:50 AM

11:00-11:50 AM 8:00-8:50 AM 5117 5115 5219 5111 5113 5117 5115 5219 5111 5117 5115 5219 5113 5115/5219 5111 5121 01/08 #1 9- MAKE UP 5111 or OR PM See PM See 5113 CH2 S. SCRIPTS 10:00 1- Schedule Schedule Salk 456 or Biosignaling

More information

Clinical Policy: CNS Stimulants Reference Number: CP.PMN.XX Effective Date: Last Review Date: Line of Business: Commercial, Medicaid

Clinical Policy: CNS Stimulants Reference Number: CP.PMN.XX Effective Date: Last Review Date: Line of Business: Commercial, Medicaid Clinical Policy: Reference Number: CP.PMN.XX Effective Date: 03.01.18 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Principals and dosage forms of pharmaceutics

Principals and dosage forms of pharmaceutics Principals and dosage forms of pharmaceutics Part II. Semisolid dosage forms: ointments, creams, gels, pastes, suppositories, pessaries 2017 Dr. Farkas, Gyula Pharmaceutical Propedeutics Institute of Pharmaceutical

More information

Wherever life takes you BASF excipients for orally disintegrating tablets make medication easy

Wherever life takes you BASF excipients for orally disintegrating tablets make medication easy Wherever life takes you BASF excipients for orally disintegrating tablets make medication easy Dr. Philipp Hebestreit, an enabler in excipients Pharma Ingredients & Services. Welcome to more opportunities.

More information

INFORMATION TOPIC: II-5 OR DEMONSTRATION: II-5. DOSAGE, MEASUREMENTS, AND DRUG FORMS (Lesson Title) OBJECTIVES THE STUDENT WILL BE ABLE TO:

INFORMATION TOPIC: II-5 OR DEMONSTRATION: II-5. DOSAGE, MEASUREMENTS, AND DRUG FORMS (Lesson Title) OBJECTIVES THE STUDENT WILL BE ABLE TO: LESSON PLAN: 5 COURSE TITLE: UNIT: II MEDICATION TECHNICIAN GENERAL PRINCIPLES SCOPE OF UNIT: This unit includes medication terminology, dosage, measurements, drug forms, transcribing physician s orders,

More information

ADDITIONAL DOSAGE STRENGTHS OF OTREXUP (METHOTREXATE) INJECTION APPROVED BY FDA

ADDITIONAL DOSAGE STRENGTHS OF OTREXUP (METHOTREXATE) INJECTION APPROVED BY FDA ADDITIONAL DOSAGE STRENGTHS OF OTREXUP (METHOTREXATE) INJECTION APPROVED BY FDA Now Available 12.5 mg/0.4 ml, 17.5 mg/0.4 ml and 22.5 mg/0.4 ml EWING, N.J., March 29, 2016 Antares Pharma, Inc. (NASDAQ:

More information

What's Important to Consider When Developing a Complex Generic Drug? September 5, 2018

What's Important to Consider When Developing a Complex Generic Drug? September 5, 2018 What's Important to Consider When Developing a Complex Generic Drug? September 5, 2018 Session Description FDA has provided drug manufacturers tools to assist the development of complex generic drugs to

More information

PEDIATRIC PATIENTS, THROUGH 2013 ($ MILLIONS) TABLE 9 SURGICAL COSTS FOR MYRINGOTOMY IN U.S. Adenoidectomy and Tonsillectomy...

PEDIATRIC PATIENTS, THROUGH 2013 ($ MILLIONS) TABLE 9 SURGICAL COSTS FOR MYRINGOTOMY IN U.S. Adenoidectomy and Tonsillectomy... CHAPTER ONE: INTRODUCTION... 1 STUDY GOAL AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 INTENDED AUDIENCE... 2 SCOPE OF REPORT... 2 INFORMATION SOURCES... 2 ANALYST S CREDENTIALS... 3 RELATED BCC

More information

CHAPTER ONE: EXECUTIVE SUMMARY

CHAPTER ONE: EXECUTIVE SUMMARY CHAPTER ONE: EXECUTIVE SUMMARY Introduction Scope and Methodology Size and Growth of the Market Issues and trends Leading Competitors CHAPTER TWO: INTRODUCTION AND OVERVIEW Definition of Pain Magnitude

More information

<1151> Pharmaceutical Dosage Forms and <1152> Animal Drugs for Use in Animal Feeds

<1151> Pharmaceutical Dosage Forms and <1152> Animal Drugs for Use in Animal Feeds Pharmaceutical Dosage Forms and Animal Drugs for Use in Animal Feeds Will Brown Veterinary Drugs Stakeholder Forum February 19-20, 2014 Development of a Compendial Taxonomy and Glossary for

More information

UnitedHealthcare Pharmacy Clinical Pharmacy Programs. Program Number 2017 P Prior Authorization/Notification CNS Stimulants

UnitedHealthcare Pharmacy Clinical Pharmacy Programs. Program Number 2017 P Prior Authorization/Notification CNS Stimulants UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1020-6 Program Prior Authorization/Notification CNS Stimulants Medication Adderall* (amphetamine-dextroamphetamine mixed salts),

More information

Drug Therapy Following Bariatric Surgery

Drug Therapy Following Bariatric Surgery Drug Therapy Following Bariatric Surgery Linda F. McElhiney PharmD, RPh, MSP, FIACP, FACA, FASHP, DPLA Compounding Pharmacist Indiana University Health Disclosures Dr. McElhiney declare(s) no conflicts

More information

Just the Basics: Pharmacology for the EMT

Just the Basics: Pharmacology for the EMT Just the Basics: Pharmacology for the EMT Make sure and document: Name of the Medications Signs and Symptoms of pt and why you gave it. Pertinant history to justify medication How you assisted the patient

More information

ORALLY DISINTEGRATING TABLETS: BRIDGING THE DIVIDE FOR COMPLIANCE

ORALLY DISINTEGRATING TABLETS: BRIDGING THE DIVIDE FOR COMPLIANCE ORALLY DISINTEGRATING TABLETS: BRIDGING THE DIVIDE FOR COMPLIANCE Joseph A. Zeleznik Associated Director R&D JRS PHARMA 2981 Route 22; Suite 1 Patterson, NY 12563 j.zeleznik@jrspharma.com What Drives the

More information

Ingredient Listing Qty. Unit NDC # Supplier

Ingredient Listing Qty. Unit NDC # Supplier 7/12/2015; Page 1 SUGGESTED FORMULATION Ingredient Listing Qty. Unit NDC # Supplier Tramadol Hydrochloride, EP 0.300 g Stevia Powder 0.15 g Glycerin, USP** 3.0 ml Beef Flavor (Powder) 2.00 g Chew-A-Treat

More information

Draft Guideline on Pharmaceutical Development of Medicines for Paediatric Use. C. Nopitsch-Mai London 1

Draft Guideline on Pharmaceutical Development of Medicines for Paediatric Use. C. Nopitsch-Mai London 1 Draft Guideline on Pharmaceutical Development of Medicines for Paediatric Use C. Nopitsch-Mai 08-11-2011 London 1 Content - Background - Pharmaceutical Problems - Scope - Characterisation of the Active

More information

OVERVIEW FOOD AND DRUG ADMINISTRATION-APPROVED INDICATIONS

OVERVIEW FOOD AND DRUG ADMINISTRATION-APPROVED INDICATIONS Pharmacy Medical Necessity Guidelines: Effective: September 18, 2017 Prior Authorization Required Type of Review Care Management Not Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit

More information

Routes of drug administration

Routes of drug administration Routes of drug administration Definition:- A route of administration in pharmacy is the path by which a drug is taken into the body. Classification:- The various routes of administrations are classified

More information

QUANTITY LIMIT CRITERIA

QUANTITY LIMIT CRITERIA DRUG CLASS (ADHD) AGENTS BRAND NAME (generic) QUANTITY LIMIT CRITERIA ATTENTION DEFICIT HYPERACTIVITY DISORDER ADDERALL (amphetamine mixture) ADDERALL XR (amphetamine extended-release mixture) ADZENYS

More information

Medication Administration. By: Carolyn McCune RN, BSN, MSN, CRNP

Medication Administration. By: Carolyn McCune RN, BSN, MSN, CRNP Medication Administration By: Carolyn McCune RN, BSN, MSN, CRNP Percutaneous Administration Medications application to the skin or mucus membranes Ointments, creams, powders, lotions, solutions into the

More information

Easy, fast and reliable!

Easy, fast and reliable! Product Overview Easy, fast and reliable! Special easy-to-use preparations for film coating, sugar-coating, colouring and tabletting. Tailormade formulated. s film coating products are one-step coating

More information

PEDIATRIC PHARMACOTHERAPY

PEDIATRIC PHARMACOTHERAPY PEDIATRIC PHARMACOTHERAPY Volume 22 Number 10 October 2016 T Amphetamine Orally Disintegrating Tablets: Another Option for the Treatment of Attention Deficit Hyperactivity Disorder Marcia L. Buck, PharmD,

More information

Chapter 7. National EMS Education Standard Competencies (1 of 5) National EMS Education Standard Competencies (2 of 5) Principles of Pharmacology

Chapter 7. National EMS Education Standard Competencies (1 of 5) National EMS Education Standard Competencies (2 of 5) Principles of Pharmacology Chapter 7 Principles of Pharmacology National EMS Education Standard Competencies (1 of 5) Pharmacology Applies fundamental knowledge of the medications that the EMT may assist/administer to a patient

More information

Methimazole 5 mg Oral Chewable Treats (Solid Suspension, 60 x 1 ml Treats) FIN F v2. Ingredient Listing Qty. Unit NDC # Supplier

Methimazole 5 mg Oral Chewable Treats (Solid Suspension, 60 x 1 ml Treats) FIN F v2. Ingredient Listing Qty. Unit NDC # Supplier 11/23/2015; Page 1 SUGGESTED FORMULATION Ingredient Listing Qty. Unit NDC # Supplier Methimazole, USP 0.300 g Tuna Flavor 1.50 g Glycerin, USP** 6.0 ml Chew-A-Treat Compound A 22.80 g Chew-A-Treat Compound

More information

Acorda Acquisition of Civitas Therapeutics. September 24, 2014

Acorda Acquisition of Civitas Therapeutics. September 24, 2014 Acorda Acquisition of Civitas Therapeutics September 24, 2014 Forward Looking Statement This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform

More information

Electronic Prescription Service (EPS) dm+d and Prescribing Systems

Electronic Prescription Service (EPS) dm+d and Prescribing Systems Electronic Prescription Service (EPS) dm+d and Prescribing Systems dm+d and Prescribing Systems The NHS Dictionary of Medicines and Devices (dm+d) is the standard for transferring medicine and medical

More information

Magellan Rx. A smarter approach to pharmacy benefits management

Magellan Rx. A smarter approach to pharmacy benefits management Magellan Rx A smarter approach to pharmacy benefits management Presented by: Cheri Caruso, VP of Sales, Magellan Rx Management Bryce Canfield, VP, Client Development, GoodRx A unique vision of care We

More information

Q1 FY02/2014 Results

Q1 FY02/2014 Results Hisamitsu Pharmaceutical Co., Inc. FY02/2014 Results This presentation material contains information that constitutes forwardlooking statements. Such forward-looking statements are not guarantees of future

More information

BDSI Corporate Overview

BDSI Corporate Overview BDSI Corporate Overview June 2017 1 2017 BioDelivery Sciences International Inc. All Rights Reserved. Jefferies 2017 Healthcare Conference Dr. Mark A. Sirgo President and Chief Executive Officer June 6

More information

300 3PORTUGUESE 65M GLOBAL WHO WE ARE WE OFFER PORTUGUESE

300 3PORTUGUESE 65M GLOBAL WHO WE ARE WE OFFER PORTUGUESE WHO WE ARE PORTUGUESE WE OFFER Licensing out Contract Manufacturing Packaging Services EU Batch Release R&D Services Marketing & Distribution Medinfar is a fully integrated Pharmaceutical Company with

More information

Iroko Pharmaceuticals Gains Additional Patents for ZORVOLEX and TIVORBEX TM

Iroko Pharmaceuticals Gains Additional Patents for ZORVOLEX and TIVORBEX TM Iroko Pharmaceuticals Gains Additional Patents for ZORVOLEX and TIVORBEX TM PHILADELPHIA, April 8, 2015 Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the

More information

Division 1 Introduction to Advanced Prehospital Care

Division 1 Introduction to Advanced Prehospital Care Division 1 Introduction to Advanced Prehospital Care Chapter 7 Intravenous Access and Medication Administration Part 1 Principles and Routes of Medication Administration Topics Aseptic Technique Medication

More information

P.L.E.A.S.E. transdermal protein delivery. DDP 2011, Miami

P.L.E.A.S.E. transdermal protein delivery. DDP 2011, Miami P.L.E.A.S.E. transdermal protein delivery DDP 2011, Miami Pantec Biosolutions at a glance Breakthrough needle-less intraepidermal delivery system P.L.E.A.S.E P.L.E.A.S.E stands for Precise Laser EpidermAl

More information

Medications: Non-Oral Administration Work Sheet

Medications: Non-Oral Administration Work Sheet Medications: Non-Oral Administration Work Sheet Name: Date: Name of Trainer: Name of Company Developing Material: Clinical Update (NZ) Ltd Contents Segment 1 - Ointments and Creams... 1 Segment 2 - Eye,

More information

J.P. Morgan Healthcare Conference

J.P. Morgan Healthcare Conference J.P. Morgan Healthcare Conference Shire plc January 10, 2012 Angus Russell Chief Executive Officer Our purpose We enable people with life-altering conditions to lead better lives. THE SAFE HARBOR STATEMENT

More information

LubriTose Mannitol Michael Crowley, Director of R&D, Excipients

LubriTose Mannitol Michael Crowley, Director of R&D, Excipients LubriTose Mannitol Michael Crowley, Director of R&D, Excipients Introduction Michael Crowley Director of R&D Excipients 158 St. Highway 320 Norwich, NY 13815 PH 315-802-5970 Michael.Crowley@Kerry.com 2

More information

Q3 18 Earnings Supplemental Slides

Q3 18 Earnings Supplemental Slides (Nasdaq: INSY) Q3 18 Earnings Supplemental Slides November 5, 2018 Safe-Harbor Statement This presentation contains both historical information and forward-looking statements. Forward-looking statements

More information

Egalet Corporate Presentation

Egalet Corporate Presentation Egalet Corporate Presentation Specialty Pharmaceutical Company Focused on Pain 1 NASDAQ: EGLT Forward-Looking Statements Statements included in this presentation that are not historical in nature are "forward-looking

More information

Scope and Methodology Size and Growth of the Market Issues and Trends Affecting the Rx-to-OTC Switches Market Leading Competitors

Scope and Methodology Size and Growth of the Market Issues and Trends Affecting the Rx-to-OTC Switches Market Leading Competitors TABLE OF CONTENTS CHAPTER ONE: EXECUTIVE SUMMARY Scope and Methodology Size and Growth of the Market Issues and Trends Affecting the Rx-to-OTC Switches Market Leading Competitors CHAPTER TWO: INTRODUCTION

More information

Howida Kamal, Ph.D Ass. Prof. of Pharmaceutics, Cairo University

Howida Kamal, Ph.D Ass. Prof. of Pharmaceutics, Cairo University Pharmacy Howida Kamal, Ph.D Ass. Prof. of Pharmaceutics, Cairo University Pharmacy Pharmacy Pharmaceutics The science of dosage form design. Pharmacy 1. 2. 3. Dosage forms Information Resources Use of

More information

ALLERGIES ARE OUT THERE.

ALLERGIES ARE OUT THERE. ALLERGIES ARE OUT THERE. DID YOU KNOW THAT DOGS AND CATS CAN HAVE ALLERGIES TOO? Some people are affected by allergies and experience itching or other symptoms that cause discomfort. Our dogs and cats

More information

Fluoxetine Hydrochloride 5.6 mg Oral Chewable Treats (Solid Suspension, 60 x 1 ml Chewable Treats)

Fluoxetine Hydrochloride 5.6 mg Oral Chewable Treats (Solid Suspension, 60 x 1 ml Chewable Treats) 4/11/2015; Page 1 Note: Fluoxetine Hydrochloride 5.6 mg is equivalent to Fluoxetine 5 mg. SUGGESTED FORMULATION Ingredient Listing Qty. Unit NDC # Supplier Fluoxetine Hydrochloride, USP 0.336 g Glycerin

More information

Managing Your OTC Medications. A Pharmacy Guide to Self- Care

Managing Your OTC Medications. A Pharmacy Guide to Self- Care Managing Your OTC Medications A Pharmacy Guide to Self- Care An ounce of prevention... Regular exercise Low-fat/highfiber diet Moderate alcohol consumption Stop smoking! Get plenty of rest Watch your

More information

Chapter 7, Medication Administration Part 1 Principles and Routes of Medication Administration Caution: Administering medications is business Always

Chapter 7, Medication Administration Part 1 Principles and Routes of Medication Administration Caution: Administering medications is business Always 1 3 4 5 6 7 8 9 10 Chapter 7, Medication Administration Part 1 Principles and Routes of Medication Administration Caution: Administering medications is business Always take appropriate Standard measures

More information

Patient Information Montelukast Sodium Tablets and Montelukast Sodium Chewable Tablets

Patient Information Montelukast Sodium Tablets and Montelukast Sodium Chewable Tablets Patient Information Montelukast Sodium Tablets and Montelukast Sodium Chewable Tablets Read the Patient Information Leaflet that comes with montelukast sodium before you start taking it and each time you

More information

Pharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications

Pharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications Pharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications Effective: November 13, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review

More information

Merrill Lynch Healthcare Conference New York

Merrill Lynch Healthcare Conference New York Merrill Lynch Healthcare Conference New York Matthew Emmens Chief Executive Officer February 3, 2004 A Strategic Review Today and Beyond Clear Strengths Highly successful business model Strong pipeline

More information

EXPANDING WHAT S POSSIBLE WITH THE RIGHT PARTNER. Life-saving pharmaceuticals start with high-quality ingredients

EXPANDING WHAT S POSSIBLE WITH THE RIGHT PARTNER. Life-saving pharmaceuticals start with high-quality ingredients EXPANDING WHAT S POSSIBLE WITH THE RIGHT PARTNER Life-saving pharmaceuticals start with high-quality ingredients CONFIDENCE STRAIGHT FROM THE SOURCE From oral dosage excipients (Rx, Gx, nutraceuticals

More information

Products that contain medications that the FDA calls drugs will list Drug Facts on the label and may include:

Products that contain medications that the FDA calls drugs will list Drug Facts on the label and may include: Topical Over-The-Counter (OTC) Medications All content must be TAUGHT by nurses or staff with current DODD Category 1 Certification. TEACH. DO NOT give to personnel to just read. OVERVIEW Most drugs can

More information

Controlled Delivery of Biologics NBC 22 June 2009

Controlled Delivery of Biologics NBC 22 June 2009 Controlled Delivery of Biologics NBC 22 June 2009 ivery System Overview, Chris Rhodes, Amylin ulatory Perspectives, Mei-Ling Chen,FDA tained Circulation Strategies, Tim Riley, Nektar nsdermal Microporation,

More information

Easy, fast and reliable!

Easy, fast and reliable! Product Overview Easy, fast and reliable! Special easy-to-use preparations for film coating, sugar-coating, colouring and tabletting. s film coating products are one-step coating systems for pharmaceutical

More information

Corium Investor Update 16 th Annual Needham Healthcare Conference

Corium Investor Update 16 th Annual Needham Healthcare Conference Nasdaq: CORI Corium Investor Update 16 th Annual Needham Healthcare Conference April 4-5, 2017 Forward-looking Statements This presentation and the accompanying oral presentation contain forward-looking

More information

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market

More information

Cantor Global Healthcare Conference

Cantor Global Healthcare Conference Nasdaq: CORI Cantor Global Healthcare Conference September 2017 Forward-looking Statements This presentation and the accompanying oral presentation contain forward-looking statements that are based on

More information

BALCHEM CORPORATION. Q Investor Relations Presentation

BALCHEM CORPORATION. Q Investor Relations Presentation BALCHEM CORPORATION Q4 2017 Investor Relations Presentation Balchem Corporation Balchem develops, manufactures, and markets specialty ingredients that improve and enhance the health and well being of life

More information

REFERENCE CODE GDHC378DFR PUBLICAT ION DATE M ARCH 2014 BOTOX (MIGRAINE) - FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC378DFR PUBLICAT ION DATE M ARCH 2014 BOTOX (MIGRAINE) - FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC378DFR PUBLICAT ION DATE M ARCH 2014 BOTOX (MIGRAINE) - Executive Summary Botox: Key Metrics in the 7MM* for Migraine, 2012-2023 2012 Market Sales US $434.3m 5 EU $68.3m Japan Total

More information

UPDATE Ohana QUEST Integration Medicaid

UPDATE Ohana QUEST Integration Medicaid UPDATE Ohana QUEST Integration Medicaid Preferred Drug List June 29, 2015 Dear Provider: At the June 04, 2015 WellCare Pharmacy & Therapeutics Committee meeting, it was decided that the following changes

More information

Shire plc. Matthew Emmens, CEO

Shire plc. Matthew Emmens, CEO Shire plc Matthew Emmens, CEO THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 "SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements

More information

TIVORBEX Now Available in U.S. Pharmacies for the Treatment of Acute Pain

TIVORBEX Now Available in U.S. Pharmacies for the Treatment of Acute Pain TIVORBEX Now Available in U.S. Pharmacies for the Treatment of Acute Pain Second Low-Dose SoluMatrix NSAID from Iroko Now Available by Prescription PHILADELPHIA, June 29, 2015 Iroko Pharmaceuticals, LLC,

More information

REGULATORY UPDATES: APPROVAL, DENIALS AND AGREEMENTS REGULATORY UPDATES: APPROVAL, (CONTINUED)... 38

REGULATORY UPDATES: APPROVAL, DENIALS AND AGREEMENTS REGULATORY UPDATES: APPROVAL, (CONTINUED)... 38 CHAPTER ONE: INTRODUCTION... 1 STUDY OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 INTENDED AUDIENCE... 2 SCOPE OF THE STUDY... 2 METHODOLOGY... 2 INFORMATION SOURCES... 2 ABOUT THE AUTHOR... 3 RELATED

More information

innovative products. faster to market. reliably supplied.

innovative products. faster to market. reliably supplied. innovative products. faster to market. reliably supplied. consumer health unique consumer health solutions for otc, supplements & beauty DEVELOPMENT DELIVERY SUPPLY As a global leader in the development

More information

Is there codeine in pseudoephedrine

Is there codeine in pseudoephedrine Is there codeine in pseudoephedrine The Borg System is 10 Is there codeine in pseudoephedrine Everything you need to know about Cold Water Extraction. How to extract codeine from other painkillers (paracetamol,

More information

Irritable Bowel Syndrome - Pipeline Review, H2 2016

Irritable Bowel Syndrome - Pipeline Review, H2 2016 Report Information More information from: https://www.wiseguyreports.com/reports/752817-irritable-bowel-syndrome-pipeline-review-h2-2016 Irritable Bowel Syndrome - Pipeline Review, H2 2016 Report / Search

More information

Part 1 Principles and Routes of Medication Administration

Part 1 Principles and Routes of Medication Administration 1 Chapter 7, Medication Administration Part 1 Principles and Routes of Medication Administration 2 Caution: Administering medications is business Always take appropriate Standard measures to reduce your

More information

REFERENCE CODE GDHC295DFR PUBLICATION DATE NOVEMBER 2013 ELIDEL (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC295DFR PUBLICATION DATE NOVEMBER 2013 ELIDEL (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC295DFR PUBLICATION DATE NOVEMBER 2013 ELIDEL (ATOPIC DERMATITIS) Executive Summary The below mentioned table presents key metrics for Elidel in the major pharmaceutical markets: the

More information

Travel Health: Selecting, Dosing, Storing & Administering Medications for Children

Travel Health: Selecting, Dosing, Storing & Administering Medications for Children Travel Health: Selecting, Dosing, Storing & Administering Medications for Children B. Seifert, Pharm.D., FCSHP Pediatric Clinical Pharmacist WRHA Regional Pharmacy Program April 2009 bseifert@hsc.mb.ca

More information

Cell Membranes, Epithelial Barriers and Drug Absorption p. 1 Introduction p. 2 The Plasma Membrane p. 2 The phospholipid bilayer p.

Cell Membranes, Epithelial Barriers and Drug Absorption p. 1 Introduction p. 2 The Plasma Membrane p. 2 The phospholipid bilayer p. Cell Membranes, Epithelial Barriers and Drug Absorption p. 1 Introduction p. 2 The Plasma Membrane p. 2 The phospholipid bilayer p. 3 Dynamic behaviour of membranes p. 4 Modulation of membrane fluidity

More information

FORMULATION DEVELOPMENT - A QbD Approach to Develop Extended Release Softgels

FORMULATION DEVELOPMENT - A QbD Approach to Develop Extended Release Softgels Seite 1 von 8 Share this story: Issue: April 2015, Posted Date: 3/30/2015 FORMULATION DEVELOPMENT - A QbD Approach to Develop Extended Release Softgels INTRODUCTION Soft gelatin capsules (softgels) continue

More information

UNIT 2 SOLID AND LIQUID DOSAGE FORMS

UNIT 2 SOLID AND LIQUID DOSAGE FORMS UNIT 2 SOLID AND LIQUID DOSAGE FORMS Solid and Liquid Structure 2.1 Introduction Objectives 2.2 Solid Tablets Capsules 2.3 Liquid Advantages of Liquid Disadvantages of Liquid Classification of Liquid Monophasic

More information

STRATTERA (Stra-TAIR-a)

STRATTERA (Stra-TAIR-a) 1 A 0.01 NL 5858 AMP MEDICATION GUIDE STRATTERA (Stra-TAIR-a) (atomoxetine) Capsules Read the Medication Guide that comes with STRATTERA before you or your child starts taking it and each time you get

More information

Pharmaceutical Preparation For Internal Use

Pharmaceutical Preparation For Internal Use Pharmaceutical Preparation For Internal Use 1. Solid Preparations (Tablet, Capsule, Pill) 2. Liquid Preparations (Aqua, Syrup, Elixir, Extract, Liquor, Emulsion, Mixture, Infusion, Decoction). 3. Powder

More information